Synergy Pharmaceuticals (SGYP) Reaches $4.34 After 4.00% Down Move; Allison Transmission Holdings (ALSN) Had 7 Bulls

June 29, 2017 - By Ellis Scott

The stock of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) is a huge mover today! About 2.59M shares traded. Synergy Pharmaceuticals Inc (NASDAQ:SGYP) has risen 24.44% since June 29, 2016 and is uptrending. It has outperformed by 7.74% the S&P500.The move comes after 6 months negative chart setup for the $1000.00M company. It was reported on Jun, 29 by Barchart.com. We have $4.17 PT which if reached, will make NASDAQ:SGYP worth $40.00M less.

Among 16 analysts covering Allison Transmission Holdings (NYSE:ALSN), 7 have Buy rating, 2 Sell and 7 Hold. Therefore 44% are positive. Allison Transmission Holdings had 35 analyst reports since July 30, 2015 according to SRatingsIntel. The stock of Allison Transmission Holdings Inc (NYSE:ALSN) earned “Outperform” rating by CLSA on Friday, September 30. On Wednesday, December 2 the stock rating was initiated by Avondale with “Mkt Outperform”. RBC Capital Markets initiated Allison Transmission Holdings Inc (NYSE:ALSN) rating on Tuesday, March 15. RBC Capital Markets has “Outperform” rating and $30 target. The stock of Allison Transmission Holdings Inc (NYSE:ALSN) has “Overweight” rating given on Wednesday, October 12 by Barclays Capital. As per Friday, April 28, the company rating was maintained by Piper Jaffray. As per Tuesday, January 24, the company rating was upgraded by Citigroup. The stock has “Neutral” rating by Macquarie Research on Tuesday, December 13. On Wednesday, September 7 the stock rating was initiated by Deutsche Bank with “Hold”. PiperJaffray downgraded the stock to “Underweight” rating in Friday, December 9 report. Barclays Capital maintained the stock with “Overweight” rating in Thursday, April 20 report. See Allison Transmission Holdings Inc (NYSE:ALSN) latest ratings:

02/06/2017 Broker: RBC Capital Markets Rating: Buy New Target: $46.0000 Maintain
01/05/2017 Broker: Deutsche Bank Rating: Hold Old Target: $43.00 New Target: $44.00 Target Up
01/05/2017 Broker: Stifel Nicolaus Rating: Hold Old Target: $35.00 New Target: $40.00 Target Up
28/04/2017 Broker: Piper Jaffray Rating: Sell New Target: $30.00 Maintain
28/04/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $40.00 New Target: $46.00 Maintain
20/04/2017 Broker: Barclays Capital Rating: Overweight Old Target: $39.00 New Target: $44.00 Maintain
06/04/2017 Broker: Seaport Global Rating: Neutral Initiate
27/02/2017 Broker: Goldman Sachs Old Rating: Buy New Rating: Neutral Downgrade
24/01/2017 Broker: Citigroup Old Rating: Neutral New Rating: Buy Upgrade

Since January 3, 2017, it had 0 insider purchases, and 12 sales for $14.29 million activity. Kirk Randall R. sold $197,986 worth of stock. 50,000 shares valued at $1.91M were sold by Graziosi David S. on Tuesday, May 23. Dick Michael also sold $279,127 worth of Allison Transmission Holdings Inc (NYSE:ALSN) on Tuesday, May 23. The insider Dewey Lawrence E. sold $2.99M.

Allison Transmission Holdings, Inc. and its subsidiaries design and manufacture commercial and defense fully-automatic transmissions. The company has market cap of $5.78 billion. The Firm makes fully-automatic transmissions for medium- and heavy-duty commercial vehicles, and medium-and heavy-tactical United States defense vehicles. It has a 24.65 P/E ratio. The Company’s transmissions are used in a range of applications, including on-highway trucks , buses (primarily school, transit and hybrid-transit), motorhomes, off-highway vehicles and equipment (energy, mining and construction) and defense vehicles (wheeled and tracked).

Investors sentiment increased to 0.99 in 2016 Q4. Its up 0.09, from 0.9 in 2016Q3. It is positive, as 24 investors sold Allison Transmission Holdings Inc shares while 91 reduced holdings. 41 funds opened positions while 73 raised stakes. 163.18 million shares or 0.39% more from 162.55 million shares in 2016Q3 were reported. Delaware-based Dupont Corp has invested 0.18% in Allison Transmission Holdings Inc (NYSE:ALSN). Pnc Fin Svcs holds 0% of its portfolio in Allison Transmission Holdings Inc (NYSE:ALSN) for 23,074 shares. Kessler Inv Group Inc Ltd Llc reported 752 shares stake. Pub Employees Retirement Association Of Colorado invested 0% of its portfolio in Allison Transmission Holdings Inc (NYSE:ALSN). Trexquant L P has invested 0.07% in Allison Transmission Holdings Inc (NYSE:ALSN). 1.21 million are owned by Ridgeworth Mgmt Limited Liability Company. Skytop Cap Ltd Company invested in 3.15% or 155,000 shares. Eagle Asset Mgmt reported 497,136 shares. Great West Life Assurance Can invested in 0% or 14,081 shares. Massachusetts Fincl Ser Com Ma invested 0.08% in Allison Transmission Holdings Inc (NYSE:ALSN). Enterprise Financial Service owns 187 shares for 0% of their portfolio. Howe & Rusling reported 0% of its portfolio in Allison Transmission Holdings Inc (NYSE:ALSN). Point72 Asset Management Lp accumulated 119,000 shares. Citigroup holds 232,122 shares or 0.01% of its portfolio. Swiss Natl Bank has 235,900 shares.

About 1.16 million shares traded. Allison Transmission Holdings Inc (NYSE:ALSN) has risen 38.35% since June 29, 2016 and is uptrending. It has outperformed by 21.65% the S&P500.

Synergy Pharmaceuticals Inc. is a biopharmaceutical firm focused on the development and commercialization of gastrointestinal therapies. The company has market cap of $1000.00 million. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. It currently has negative earnings. The Firm is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Investors sentiment decreased to 1.19 in 2016 Q4. Its down 0.60, from 1.79 in 2016Q3. It is negative, as 19 investors sold Synergy Pharmaceuticals Inc shares while 43 reduced holdings. 27 funds opened positions while 47 raised stakes. 113.25 million shares or 15.05% more from 98.44 million shares in 2016Q3 were reported. Financial Bank Of Montreal Can reported 0% stake. Palisade Management Ltd Liability Nj holds 0.09% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) for 413,882 shares. Legal General Gp Public Limited reported 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Blackrock Japan Co Limited reported 800 shares or 0% of all its holdings. Morgan Stanley owns 1.21 million shares for 0% of their portfolio. State Board Of Administration Of Florida Retirement Systems stated it has 66,421 shares or 0% of all its holdings. Secor Advisors L P has invested 0.07% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Gp One Trading Ltd Partnership stated it has 0.03% of its portfolio in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Century Companies reported 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Landscape Capital Management Ltd Llc owns 153,376 shares. Parallax Volatility Advisers Lp reported 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Credit Agricole S A holds 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) or 4,497 shares. Comml Bank Of America De invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). The Switzerland-based Credit Suisse Ag has invested 0% in Synergy Pharmaceuticals Inc (NASDAQ:SGYP). Price T Rowe Assoc Md, Maryland-based fund reported 43,107 shares.

Since May 26, 2017, it had 2 insider purchases, and 0 selling transactions for $43,302 activity. On Friday, May 26 the insider BRANCACCIO JOHN P bought $23,335. $19,967 worth of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) was bought by JACOB GARY S.